Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9323964 | 0.89 | SMN1; SMN2 (0.53) | GSK3BMAP2K4SMN1; SMN2EGFRNR4A2 | |
| SCHEMBL13172609 | 0.86 | ALDH1A1 (0.55) | GSK3BMAP2K4SMN1; SMN2 | |
| SCHEMBL14564361 | 0.84 | SMN1; SMN2 (0.55) | GSK3BMAP2K4SMN1; SMN2NR4A2MAPT | |
| SCHEMBL6016609 | 0.83 | SMN1; SMN2 (0.53) | GSK3BMAP2K4SMN1; SMN2MAPT | |
| SCHEMBL6612568 | 0.82 | GSK3B (0.56) | GSK3BMAP2K4KMT2A | |
| SCHEMBL25139872 | 0.82 | GSK3B (0.53) | GSK3BMAP2K4 | |
| SCHEMBL25139869 | 0.81 | GSK3B (0.49) | GSK3BMAP2K4 | |
| SCHEMBL4300704 | 0.80 | SMN1; SMN2 (0.71) | SMN1; SMN2EGFRMAPT | |
| SCHEMBL6016433 | 0.79 | SMN1; SMN2 (0.49) | GSK3BSMN1; SMN2MAPTPOLBKMT2A | |
| SCHEMBL119757 | 0.76 | ALDH1A1 (0.55) | GSK3BSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723705-B2 | Heterocyclic compounds and uses thereof | INCYTE CORPORATION (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723705-B2 | Heterocyclic compounds and uses thereof | HDAC8, HDAC1, HDAC5 | GSK3B 951/4885MAP2K4 3618/4885SMN1; SMN2 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.